Last reviewed · How we verify
Suvorexant tablets, over-encapsulated — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Suvorexant tablets, over-encapsulated (Suvorexant tablets, over-encapsulated) — Eisai Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Suvorexant tablets, over-encapsulated TARGET | Suvorexant tablets, over-encapsulated | Eisai Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Suvorexant tablets, over-encapsulated CI watch — RSS
- Suvorexant tablets, over-encapsulated CI watch — Atom
- Suvorexant tablets, over-encapsulated CI watch — JSON
- Suvorexant tablets, over-encapsulated alone — RSS
Cite this brief
Drug Landscape (2026). Suvorexant tablets, over-encapsulated — Competitive Intelligence Brief. https://druglandscape.com/ci/suvorexant-tablets-over-encapsulated. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing